Table 1.
Food and Drug Administration approved monoclonal antibodies for therapy of solid tumors
| Antibody | Trade name | Target | Indication |
|---|---|---|---|
| Cetuximab | Erbitux® | EGFR | CRC (m), SCCHN (loc ad, rec) |
| Panitumumab | Vectibix® | EGFR | CRC (m) |
| Trastuzumab | Herceptin® | HER2 | BC (ad, m), AC of GE junction |
| Bevacizumab | Avastin® | VEGF | CRC (m), SCCHN (loc ad, rec), BC (m), RCC (ad), glioblastoma |
| Girentuximab | Rencarex® | Carbonic anhydrase IX | RCC |
| Ipilimumab | Yervoy® | CTLA-4 | MM (met) |
Abbreviations: AC, adenocarcinoma; ad, advanced; BC, breast cancer; CRC, colorectal cancer; CTLA-4, cytotoxic T lymphocyte antigen-4; EGFR, epidermal growth factor receptor; GE, gastroesophageal; HER2, human epidermal growth factor receptor-2; loc adv, locally advanced; m, metastatic; MM, malignant melanoma; RCC, renal cell carcinoma; rec, recurrent; SCCHN, squamous cell carcinoma of the head and neck; VEGF, vascular endothelial growth factor.